Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
Dr. Sascha Dublin tells how studies of KP electronic health record data can improve COVID-19 treatment and prevention.
A registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
Take these tips from researchers on the Society of Behavioral Medicine’s Physical Activity Special Interest Group.
Dr. Jennifer Nelson explains how Kaiser Permanente scientists are helping the CDC and FDA keep an eye out for rare adverse events.
Dr. Diana Buist reflects on the challenges of providing screening during a pandemic — and finds reason for optimism.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.